Patent: 10,047,163
✉ Email this page to a colleague
Summary for Patent: 10,047,163
Title: | Multispecific constructs |
Abstract: | Provided are novel multispecific antibody constructs and multispecific antibody drug conjugates (ADCs), and methods of using such antibodies and ADCs to treat cancer. IgG-like bispecific antibodies have different binding specificities on each arm of the antibody. They are similar in structure to monospecific IgGs in that they contain two heavy chains with VH, CH1, CH2 and CH3 regions, and two light chains with VL and CL regions. |
Inventor(s): | Liu; David (San Francisco, CA) |
Assignee: | AbbVie Stemcentrx LLC (North Chicago, IL) |
Application Number: | 14/765,861 |
Patent Claims: | see list of patent claims |
Details for Patent 10,047,163
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | November 26, 1997 | ⤷ Subscribe | 2033-02-08 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | September 25, 1998 | ⤷ Subscribe | 2033-02-08 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | February 10, 2017 | ⤷ Subscribe | 2033-02-08 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | May 07, 2001 | ⤷ Subscribe | 2033-02-08 |
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | November 14, 2014 | ⤷ Subscribe | 2033-02-08 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | October 12, 2004 | ⤷ Subscribe | 2033-02-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |